Hospira/Celltrion: Don't Let U.S. Biosimilar Law's Questions 'Percolate'
This article was originally published in Scrip
Executive Summary
Questions raised in an ongoing lawsuit filed by Amgen involving Novartis unit Sandoz's Zarxio (filgrastim-sndz) about the notice of commercial marketing provision in the Biologics Price Competition and Innovation Act (BPCIA) are vital to the competition and functioning of the multibillion dollar biosimilars industry and should not be allowed to "percolate" and must be answered now, Hospira and Celltrion said in a brief filed on Sept. 3.